GBT 440

Drug Profile

GBT 440

Alternative Names: GBT440; GTx-011

Latest Information Update: 07 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Global Blood Therapeutics
  • Class Antianaemics; Small molecules
  • Mechanism of Action Abnormal haemoglobin modulators; Sickle haemoglobin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Sickle cell anaemia
  • Phase II Idiopathic pulmonary fibrosis
  • Phase I Hypoxia; Liver disorders

Most Recent Events

  • 05 Sep 2017 GBT 440 receives Rare Paediatric Disease designation from the FDA for Sickle cell disease
  • 07 Aug 2017 Pharmacodynamics data from a preclinical trial in Idiopathic pulmonary fibrosis released by Global Blood Therapeutics
  • 28 Jun 2017 GBT 440 receives Priority Medicine (PRIME) status for Sickle cell anaemia in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top